WEBULL
WebtradeDownload

Johnson & Johnson (JNJ) Stock May Be 42% Undervalued Despite Cancer Trial Results

Simply Wall St · 1d ago

Johnson & Johnson has delivered a powerful share price run in recent years, and the question now is whether the current US$275.20 level is properly supported by the cash it can generate over time. With a Discounted Cash Flow (DCF) lens available to assess those future inflows, the issue for you is how that cash flow story lines up against a stock that has already moved a long way.

  • Over the past 3 years, Johnson & Johnson has returned 99.5%, which puts a lot of weight on the assumption that its future cash flows can keep justifying a much higher valuation base than before.
  • Fresh trial results across oncology and cardiovascular products, including strong response rates in advanced cancers and new device launches, may support expectations for future treatment uptake that can influence how much free cash the business is capable of producing.
  • Prefer to judge Johnson & Johnson on earnings? See why Johnson & Johnson's 41.2x P/E tells a different valuation story.

The stock's next move may depend on whether those projected cash flows, as captured by a Discounted Cash Flow (DCF) intrinsic value estimate, are strong enough to support where Johnson & Johnson is trading today.

If you want to test the same cash flow question you are asking of Johnson & Johnson across a broader set of ideas, take a look at 30 high quality undervalued stocks.

Is Johnson & Johnson a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach here projects what Johnson & Johnson might return to shareholders in future cash, then brings those streams back to today. Latest twelve month free cash flow sits at about $20.1b, and the model assumes this pool of cash expands over time rather than shrinking.

Analyst and model estimates point to free cash flow rising into the $40b range by 2030, which helps explain why the DCF output comes in substantially above the current US$275.20 share price. The strong Phase 1 data for JNJ-6143 in advanced prostate cancer adds another possible source of future cash generation, because it underlines how much of the current pipeline story is already being treated as real in the valuation. Find out what Johnson & Johnson could be worth using our Discounted Cash Flow (DCF) estimate.

The Johnson & Johnson Narrative: What Would Justify Today's Price?

Narratives pick up where the DCF puzzle for Johnson & Johnson leaves off by spelling out which paths for growth, margins and earnings would need to hold for the share price to look meaningfully higher or lower than it does today on Simply Wall St's Community page. Each scenario ties a fair value estimate to a particular mix of potential catalysts and risks so you can track which storyline on Johnson & Johnson's future appears closer to reality over time.

Community views on Johnson & Johnson split between those who see more upside in the pipeline and MedTech buildout and those who worry about paying too much for that stability.

Bull case: roughly fairly valued

"The company's substantial investment of over $55 billion into manufacturing, R&D, and technology in the U.S. over the next four years is projected to expand capacity for advanced medicines and devices..."

Discover why this Narrative puts Johnson & Johnson at roughly fairly valued.

Bear case: 12% overvalued

"At ~22× earnings, JNJ trades near sector averages but commands a modest premium for stability, balance sheet strength, and consistent free cash flow..."

Explore why this Narrative puts Johnson & Johnson at 12% overvalued.

One more Johnson & Johnson question that could change the story

The cash flow model tells you what the business might produce, but it does not show who is steering that engine or how their incentives line up with your outcome as a shareholder. See who runs Johnson & Johnson and how they are paid.